Abera Bioscience
Abera Bioscience is a platform and vaccine development company with over 30 years of research experience in the medical, molecular, and microbiological fields. The company specializes in developing next-generation mucosal vaccines, including nasal vaccines against pneumococcal infections and influenza, aiming to improve vaccine efficacy and flexibility. Leveraging proprietary technology platforms, Abera is positioned to rapidly create new vaccine candidates, including for pandemic preparedness and influenza, where it aims to delay decision-making on virus strains for seasonal vaccines. The company is actively advancing its pipeline, which includes a universal pneumococcal vaccine candidate in clinical preparation, and is expanding into influenza and immuno-oncology. Abera has demonstrated success in developing nasal vaccines against viruses such as COVID-19 and is exploring the potential for mucosal immunization via nasal spray to prevent infection spread and outbreaks.
Industries
Nr. of Employees
small (1-50)
Abera Bioscience
Virdings allé 32, 754 50 Uppsala, Sweden
Patents
Fusion polypeptides comprising one or more inclusion body tags, methods and uses
US-11124555-B2
View DetailsDisplay of heterologous molecules on bacterial cells and membrane vesicles
US-11059868-B2
View Details
Fusion polypeptides comprising one or more inclusion body tags, methods and uses
US-11124555-B2
View DetailsDisplay of heterologous molecules on bacterial cells and membrane vesicles
US-11059868-B2
View DetailsProducts
Nasal pneumococcal vaccine candidate (lead mucosal candidate)
An OMV-based nasal vaccine candidate intended to elicit mucosal and systemic immunity against pneumococcal infections; progressed through preclinical immunogenicity and toxicology studies and prepared for Phase I clinical planning.
Nasal influenza vaccine candidate (initiated development)
Influenza vaccine candidates using an OMV-based carrier and intranasal delivery formats (spray and powder) developed as part of seasonal and pandemic preparedness activities, with workflows designed to enable rapid candidate generation and later strain-selection.
Early-stage bacterial vaccine candidates (e.g., chlamydia, tuberculosis)
Multiple early pipeline vaccine candidates using OMV and related platform technologies for bacterial indications currently in preclinical development.
Nasal pneumococcal vaccine candidate (lead mucosal candidate)
An OMV-based nasal vaccine candidate intended to elicit mucosal and systemic immunity against pneumococcal infections; progressed through preclinical immunogenicity and toxicology studies and prepared for Phase I clinical planning.
Nasal influenza vaccine candidate (initiated development)
Influenza vaccine candidates using an OMV-based carrier and intranasal delivery formats (spray and powder) developed as part of seasonal and pandemic preparedness activities, with workflows designed to enable rapid candidate generation and later strain-selection.
Early-stage bacterial vaccine candidates (e.g., chlamydia, tuberculosis)
Multiple early pipeline vaccine candidates using OMV and related platform technologies for bacterial indications currently in preclinical development.
Services
Licensing and collaborative R&D to apply a modular OMV-based vaccine platform in candidate development programs and indications outside the core pipeline.
Design and execution of preclinical immunogenicity and GLP-style toxicology studies to generate data for regulatory submissions and clinical trial entry.
Development and verification of GMP-adapted production processes and coordination with contract manufacturers and test-bed facilities for scale-up and supply.
Formulation R&D for nasal sprays and dry powders, including stability, manufacturability and delivery-format optimization.
Licensing and collaborative R&D to apply a modular OMV-based vaccine platform in candidate development programs and indications outside the core pipeline.
Design and execution of preclinical immunogenicity and GLP-style toxicology studies to generate data for regulatory submissions and clinical trial entry.
Development and verification of GMP-adapted production processes and coordination with contract manufacturers and test-bed facilities for scale-up and supply.
Formulation R&D for nasal sprays and dry powders, including stability, manufacturability and delivery-format optimization.
Expertise Areas
- Mucosal vaccine development and intranasal delivery
- OMV-based vaccine platform engineering
- Formulation for nasal spray and dry powder delivery
- Preclinical efficacy and toxicology study execution
Key Technologies
- Outer membrane vesicle (OMV) vaccine vectors
- Modular protein-tag antigen coupling
- Cell-free protein synthesis for antigen production
- Nasal spray and dry powder formulation technologies
News & Updates
Abera Bioscience announced results from a study demonstrating the potential of its vaccine platform for pandemic preparedness, highlighting long-term storage benefits.
Abera Bioscience received a CEPI grant to test bacterial OMV platform for boosting mucosal immunity in nasal vaccines.
Abera Bioscience appointed Mats Lundgren as VP R&D, with over 25 years of experience in vaccine development.
An in-depth article on mucosal vaccines and Abera's technology in this field.
Abera Bioscience's approach to developing next-generation mucosal vaccines based on proprietary platform technology.
Abera received final approval from the European Patent Office for its patent on decorating bacterial cells and OMVs with heterologous molecules.
Abera Bioscience announced results from a study demonstrating the potential of its vaccine platform for pandemic preparedness, highlighting long-term storage benefits.
Abera Bioscience received a CEPI grant to test bacterial OMV platform for boosting mucosal immunity in nasal vaccines.
Abera Bioscience appointed Mats Lundgren as VP R&D, with over 25 years of experience in vaccine development.
An in-depth article on mucosal vaccines and Abera's technology in this field.
Abera Bioscience's approach to developing next-generation mucosal vaccines based on proprietary platform technology.
Abera received final approval from the European Patent Office for its patent on decorating bacterial cells and OMVs with heterologous molecules.